MX2017013350A - Comprimido de ribociclib. - Google Patents

Comprimido de ribociclib.

Info

Publication number
MX2017013350A
MX2017013350A MX2017013350A MX2017013350A MX2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A
Authority
MX
Mexico
Prior art keywords
ribociclib
tablet
directed
present disclosure
coating
Prior art date
Application number
MX2017013350A
Other languages
English (en)
Inventor
Grandeury Arnaud
Gururajan Bindhumadhavan
Costa Rui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017013350A publication Critical patent/MX2017013350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción está dirigida al comprimido oral de ribociclib incluyendo su(s) sal(es). Una modalidad de la presente descripción se dirige al comprimido de ribociclib con alta carga de fármaco con un perfil de liberación inmediata. Una modalidad de la presente descripción se refiere a un comprimido de ribociclib recubierto. Otra modalidad de la presente descripción se refiere a un comprimido de ribociclib recubierto donde el recubrimiento es una barrera contra la humedad avanzada (por ejemplo, el recubrimiento Opadry(r) amb II donde el recubrimiento está basado en PVA).
MX2017013350A 2015-04-16 2016-04-14 Comprimido de ribociclib. MX2017013350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
MX2017013350A true MX2017013350A (es) 2018-01-25

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013350A MX2017013350A (es) 2015-04-16 2016-04-14 Comprimido de ribociclib.

Country Status (29)

Country Link
US (3) US10799506B2 (es)
EP (2) EP3283058B1 (es)
JP (1) JP2018514523A (es)
KR (1) KR20170137101A (es)
CN (2) CN107530292B (es)
AR (1) AR104257A1 (es)
AU (4) AU2016248017A1 (es)
BR (1) BR112017021283A2 (es)
CA (1) CA2982425C (es)
CL (1) CL2017002593A1 (es)
CO (1) CO2017010510A2 (es)
DK (1) DK3283058T3 (es)
EA (1) EA201792290A1 (es)
EC (1) ECSP17075052A (es)
ES (1) ES2938261T3 (es)
FI (1) FI3283058T3 (es)
HR (1) HRP20230053T1 (es)
HU (1) HUE061213T2 (es)
IL (1) IL254818A0 (es)
MX (1) MX2017013350A (es)
PE (1) PE20180035A1 (es)
PH (1) PH12017501820A1 (es)
PL (1) PL3283058T3 (es)
PT (1) PT3283058T (es)
SG (1) SG11201708084PA (es)
SI (1) SI3283058T1 (es)
TN (1) TN2017000422A1 (es)
TW (1) TW201642864A (es)
WO (1) WO2016166703A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017013350A (es) 2015-04-16 2018-01-25 Novartis Ag Comprimido de ribociclib.
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
MX2022007488A (es) 2019-12-16 2022-08-02 Lunella Biotech Inc Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
TW202329977A (zh) 2022-01-25 2023-08-01 瑞士商諾華公司 瑞博西尼藥物組成物
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
CN1097619C (zh) * 1994-07-12 2003-01-01 伯温德药品服务公司 隔潮膜涂层组合物及其生产方法以及涂层制品
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CN105853439A (zh) * 2011-02-11 2016-08-17 维斯塔实验室有限公司 吩噻嗪二胺鎓盐和其用途
KR102238970B1 (ko) * 2012-07-13 2021-04-09 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
PE20151785A1 (es) * 2013-03-21 2015-12-20 Novartis Ag Terapia de combinacion
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
MX2017013350A (es) 2015-04-16 2018-01-25 Novartis Ag Comprimido de ribociclib.
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
EP4197530A1 (en) 2023-06-21
AU2019201929A1 (en) 2019-04-11
EP3283058B1 (en) 2022-11-16
AU2020250190A1 (en) 2020-11-05
SI3283058T1 (sl) 2023-03-31
TW201642864A (zh) 2016-12-16
HRP20230053T1 (hr) 2023-03-03
CL2017002593A1 (es) 2018-05-18
DK3283058T3 (da) 2023-02-13
JP2018514523A (ja) 2018-06-07
CN107530292B (zh) 2022-11-01
US20180071292A1 (en) 2018-03-15
AR104257A1 (es) 2017-07-05
BR112017021283A2 (pt) 2018-06-26
CN107530292A (zh) 2018-01-02
CA2982425A1 (en) 2016-10-20
KR20170137101A (ko) 2017-12-12
EA201792290A1 (ru) 2018-02-28
IL254818A0 (en) 2017-12-31
WO2016166703A1 (en) 2016-10-20
HUE061213T2 (hu) 2023-05-28
CA2982425C (en) 2023-10-31
AU2022215155A1 (en) 2022-09-01
US20230104792A1 (en) 2023-04-06
EP3283058A1 (en) 2018-02-21
FI3283058T3 (fi) 2023-03-01
ECSP17075052A (es) 2018-02-28
TN2017000422A1 (en) 2019-01-16
PL3283058T3 (pl) 2023-03-20
PE20180035A1 (es) 2018-01-09
AU2016248017A1 (en) 2017-10-19
PT3283058T (pt) 2023-02-03
US10799506B2 (en) 2020-10-13
US20200390771A1 (en) 2020-12-17
PH12017501820A1 (en) 2018-04-23
AU2019201929B2 (en) 2020-07-09
ES2938261T3 (es) 2023-04-05
CN115554257A (zh) 2023-01-03
CO2017010510A2 (es) 2018-03-20
SG11201708084PA (en) 2017-10-30

Similar Documents

Publication Publication Date Title
PH12017501820A1 (en) Ribociclib tablet
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
EP3362930A4 (en) SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS
EP3038539A4 (en) Heart anchor positioning devices, methods, and systems for treatment of congestive heart failure and other conditions
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP3466943A4 (en) DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3334719A4 (en) SUBSTITUTED BENZIMIDAZOLES, PREPARATION AND USE THEREOF AS PHARMACEUTICAL AGENTS
PH12015502783A1 (en) Delayed release cysteamine bead formulation
EP3386505A4 (en) AZA-BENZIMIDAZOLA INHIBITORS OF PAD4
IN2015DN01286A (es)
EP3386952A4 (en) SUBSTITUTED BENZIMIDAZOLIUM, PYRIDO-IMIDAZOLIUM OR PYRAZINO-IMIDAZOLIUM COMPOUNDS AS CHEMOTHERAPEUTICS
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
EP3124486A4 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
IL280641A (en) Converted benzimidazoles as PAD4 inhibitors
EP3252118A4 (en) Aqueous coating composition
EP3256672A4 (en) Access-control fixture lock
EP3130592A4 (en) Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
EP3476850A4 (en) SUBSTITUTED BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREFOR AND APPLICATION THEREOF
SG11201705533SA (en) Levelling compound, its use and manufacture
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EP3325564A4 (en) AQUEOUS COATING COMPOSITION
GB2543709A (en) Pharmaceutical agent
EP3024427A4 (en) Derivatives of 2,2,6-trimethylcyclohexane-carboxylate
EP3712133A4 (en) SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION WITH IT